html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

ga naar hoofdinhoud

Ga naar de website van Onco Oost

Studies gynaecologische oncologie

Zoeken

vul zoekwoord in

Studies oncologie Studies gynaecologische oncologie

NEODOC

Epitheliaal ovariumcarcinoom, fase 1/2, dendritische cel vaccinatie (XP-DC)

R4018-ONC-1721

Ovariumcarcinoom, peritoneale kanker, fase I/II, hoog CA-125, cemiplimab and MUC16-antibody

Filter

NEODOC

R4018-ONC-1721